KILITCHKilitch Drugs(India)

₹389+2.88%

Market Cap

₹683.67 Cr

Stock P/E

24.41

ROCE

17.31%

ROE

13.20%

Book Value

₹145.39

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Public

From Last Concall

POSITIVES

•
Khopoli Green Field project to manufacture multiple dosage forms, targeting WHO/EU/USFDA standards and reducing outsourcing.
•
Ethiopia facility secured first order worth USD 9.13 million; currency risk absorbed (55% of order in foreign currency).

NEGATIVES

•
Historical Ethiopian capacity utilization is low (5-7% YoY), signaling execution risk if footprint scales faster than demand.
•
Receivable days have increased; Africa-related working capital risk; plan to focus on advances.

Peers Summary

Sector Leader

Kilitch Drugs (India) Ltd. demonstrates strong growth potential with a respectable profitability profile, making it competitive within the pharmaceuticals sector, particularly against peers with higher valuations. However, some companies stand out as better value picks and stronger performers overall.

Key Points

• Kilitch Drugs shows solid revenue growth and good return metrics compared to peers.
• Sun Pharmaceuticals and Divi's Laboratories are among the most overvalued, while Kilitch presents a more attractive valuation based on its growth.
• Cipla and Dr. Reddy's Laboratories rank highly in terms of profitability and efficiency.

Top Performers

Dr. Reddy's Laboratories Ltd.

High ROE (21.76%), strong EPS growth and low PE (15.50) make it a standout.

Cipla Ltd.

Impressive profitability metrics with a reasonable PE (23.73) and solid growth.

Kilitch Drugs (India) Ltd.

Strong revenue growth (YoY: 28.47%) and decent profitability metrics (ROE: 8.43%).

Explore

Watchlists

Command Palette